Management
Management
Moncef Jendoubi, PhD, DES – President and Chief Executive Officer
Dr. Jendoubi is the founder of Milagen Inc. Since March 1999, Dr. Jendoubi has served as President and CEO leading the company maturation process. Through his leadership and vision, Milagen is developing from an R&D discovery and validation biotechnology company with a focus on tissue and serum cancer biomarkers, to a diagnostic company with an innovative line of diagnostic products for cancer surveillance and management.
Dr. Jendoubi was educated in France, and holds several degrees, including a M.S. in Genetics, in Biochemistry, a Ph.D. in Molecular Biology and a "Doctorat D'Etat es-Sciences" in Immunology. He trained at the Pasteur Institute where he held the position of Associate Professor in the Department of Immunology.
In 1987 Dr. Jendoubi joined the National Institutes of Health (NIH) as Visiting Scientist at the NIAID, then became Chief of the Genetics and Molecular Immunology Section in 1990.
Dr. Jendoubi is an internationally recognized and highly regarded scientist. He is a member of several academic societies, including the American Association of Clinical Oncology (ASCO), and the American Association for Clinical Chemistry (AACC).
Rosaura P.C. Valle, PhD – VP of Operations & Strategic Alliances
Dr. Valle is part of Milagen executive team. She has been with the Company since inception holding several key positions thus contributing to the establishment of Milagen as a research and development biotechnology company. Dr. Valle has been a key figure in establishing numerous collaborations with academic and clinical centers in the US and abroad.
As VP of Operations & Strategic Alliances since 2001, Dr. Valle oversees all operations, human resources, and intellectual property at Milagen. In addition, she is in charge of all academic collaborations, business relations, and government contracting. Dr. Valle has acquired extensive experience with government agencies, as she trained at the NIDDK of the National Institutes of Health (NIH) in Bethesda from 1989 to 1994, and spent three years at the Center for Biologics Evaluation and Research (CBER) of the Food and Drug Administration (FDA) prior to joining Milagen.
Dr. Valle received her PhD in 1989 from the University Denis Diderot in Paris, France, and is the author of a number of scientific publications in molecular virology, as well as in the applications of Milagen technologies in biomarker development and early diagnostics.
Alfredo J. Quattrone, PhD – VP of Regulatory Affairs
Dr. Quattrone has joined our team in 2009 to provide strategic guidance in regulatory affairs and compliance. Dr Quattrone is leading our effort in developing and commercializing Milagen first medical device products, in the form of immunohistochemistry reagents and kits for in vitro diagnostic use. He is also responsible for providing quality system oversight.
After a PhD in Medicinal Chemistry from the University of Pittsburgh in 1970, Dr Quattrone’s academic career developed at the National Cancer Institute of the National Institutes of Health and at the Pathology Department of the University of Texas Health Center in Dallas. From 1980 to 1985 Dr Quattrone’s career turned to industry when he joined SmithKline-Beckman Corporation as Immunochemist and Toxicologist Senior Scientist. He then dedicated over twenty years of expertise as Staff Toxicologist at the CA State Food & Drug Branch of the California Department of Health Services in Sacramento, CA, specializing in medical devices, diagnostic kits, FDA third party 510(k) submission and reviews, and quality system inspections and audits.
Dr. Quattrone is a member and diplomat of the American Board of Toxicology (DABT), the American Board of Clinical Chemistry (DACC), and has held a CA Clinical Laboratory Scientist license until 1998.
Christine Chavany, PhD – Regulatory Affairs Associate
Dr. Chavany has led Milagen research and development effort in biomarker discovery and development in cancer since inception of the company in 1997. She has been a key figure in the development of Milagen technologies, and has been Principal Investigator in several US government funded projects.
Dr. Chavany has recently joined Milagen Management Team of Regulatory Affairs to oversee the GMP manufacturing of Milagen diagnostic product pipeline, and to provide guidance in regulatory affairs and compliance, being the liaison with the FDA and other government agencies.
Dr. Chavany received her PhD in Pharmaceutical Sciences from the University of Paris XI in 1991, and trained at the National Cancer Institute from 1991 to 1997 focusing on the anti-cancer activity of antisense oligonucleotides. She has also held other positions in the biotech sector prior to joining Milagen.
Dr. Chavany is a long-lasting member of the American Association for Cancer Research, and is Regulatory Affair Certified by the Regulatory Affair Professional Society since 2001.